Abstract:Naturally occurring diabetes mellitus (NODM) is one of the most common endocrine disorders in dogs and its etiology closely resembles type 1 diabetes mellitus (T1DM) in people. Human patients with T1DM commonly have cellular derangements consistent with inflammation, impaired immune function, and hypovitaminosis D. There is little information available regarding inflammatory biomarkers, immune function, and vitamin D status in diabetic dogs. Therefore, our objectives were to assess inflammatory biomarkers, vitamin D metabolites, and phagocytic capacity in diabetic dogs and determine whether associations exist with these variables and the level of clinical control or vitamin D metabolites. This was a prospective case-control study that included 20 otherwise healthy diabetic dogs (clinically controlled, n = 10; uncontrolled, n = 10) and 20 non-diabetic, healthy, age (± 2 years), breed, and sex matched controls. Complete blood count, biochemical panel, urinalysis, and fructosamine were performed at a single commercial reference laboratory. Basal plasma tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-8, and IL-10 were measured using a canine-specific multiplex bead-based assay. Serum C-reactive protein (CRP) was measured using a commercially available ELISA kit. Serum 25-hydroxyvitamin (OH)D3 and 24,25-dihydroxyvitamin (OH)2D3 were measured with HPLC. Phagocytosis of opsonized-Escherichia coli (E. coli) was evaluated with flow cytometry. Diabetic dogs had higher serum CRP concentrations than controls (p = 0.02). Plasma IL-8 concentrations were higher in diabetic dogs with uncontrolled clinical disease compared to controls (p = 0.02). Diabetic dogs had a lower percentage of leukocytes that phagocytized opsonized-E. coli (p = 0.02), but an increased number of bacteria phagocytized per cell (p < 0.001) compared to controls. No between-group differences were identified in vitamin D metabolites, nor were associations found between vitamin D and any variables. Fructosamine had a positive association with serum CRP concentration (rho = 0.35, p = 0.03) and number of bacteria phagocytized per cell (rho = 0.45, p = 0.004) in our cohort (n = 40). Like people with T1DM, diabetic dogs have a proinflammatory phenotype and phagocytic dysregulation that may be correlated with glycemic control.

Subchronic Toxicity and Toxicokinetics of MCC-555, a Novel Thiazolidinedione, after 270-Day Repeated Oral Administration in Dogs

Quantitative determination of MCC-555, a novel insulin sensitizer in beagle dog plasma by high-performance liquid chromatography with fluorescence detection.

Genotoxicity and subchronic toxicological study of a novel ginsenoside derivative 25-OCH 3 -PPD in beagle dogs

Assessment of Thirteen-Week Subchronic Oral Toxicity of Cyadox in Beagle Dogs.

Beagle Dog 90-Day Oral Toxicity Study of a Novel Coccidiostat – Ethanamizuril

Toxicokinetics of CXY-001 Following Single and Repeated Administration to Beagle Dogs

Ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in dogs

Evaluation of serum vitamin D metabolites, phagocytosis, and biomarkers of inflammation in dogs with naturally occurring diabetes mellitus

Preclinical Toxicity of AZD7969

High-Throughput Quantification Of A Novel Thiazolidinedione Mcc-555 In Rat Plasma By Ultra-Fast Liquid Chromatography And Its Application In Pharmacokinetic Studies

Safety of TCMCB07, a melanocortin-4 antagonist peptide, in dogs with naturally occurring cachexia

Treatment of moderate-to-severe canine atopic dermatitis with modified-release mycophenolate (OKV-1001): A pilot open-label, single-arm multicentric clinical trial

Toxicity and Toxicokinetics of a Four-Week Repeated Gavage of Levamisole in Male Beagle Dogs: A Good Laboratory Practice Study

Preclinical toxicity evaluation of novel antibacterial contezolid acefosamil in rats and dogs

Subchronic toxicity and toxicokinetics of LZB, a new proton pump inhibitor, after 13-week repeated oral administration in dogs

A prospective multicenter study of the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea

Exploring montelukast in dogs: A preliminary pharmacokinetic study following oral administration under fasted and fed conditions

Toxicity of a Novel Anti-Tumor Agent 20(S)-Ginsenoside Rg3: A 26-Week Intramuscular Repeated Administration Study in Beagle Dogs

Preclinical modeling of metabolic syndrome to study the pleiotropic effects of novel antidiabetic therapy independent of obesity

28‐day repeated dose toxicity and toxicokinetics study on new melatonergic antidepressant GW117 in beagle dogs